Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Evonile Pharma Limited (NSE: EVONILE), ISIN INE234A01025 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
EVONILE last traded at ₹1670.00 (-3.04%), with a 52-week range of ₹950.00 to ₹2588.80 (as of 3 Nov 2026).
Shareholding as of Sep 2026: promoters 70.68%, FIIs 1.21%, DIIs 1.50%, mutual funds 0.77%.
EquiSense Score (ECS): 44/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.